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Objectives: HIV (Human Immunodeficiency Virus) that ultimately determines the 
development of AIDS evolved in time in a pandemic disease.  Our study evaluated first 
trimester markers for aneuploidy, serum progesterone levels in first and second trimester in 
HIV positive pregnant women under HAART therapy.  
Material and methods: It was a prospective study that took place between January 2017- 
December 2019 in ʺCuza-Vodăʺ Hospital from Romania. We analysed first trimester PAPP-
A, βHCG, first and second trimester progesterone of 25 HIV positive pregnant women under 
HAART therapy and compared them with seronegative pregnant women.  
Results: Both βHCG and first and second trimester progesterone were lower in HIV positive 
women under HAART therapy.  
Discussion: These alterations of first trimester markers for aneuploidy might lead to an over 
estimation of the risk for Down syndrome.  
Conclusions: Obstetricians need to know the alterations of first trimester markers for 
aneuploidy so they can correctly advise these women accordingly. 
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HIV (Human Immunodeficiency Virus) that ultimately determines the 
development of AIDS evolved disease in time in a pandemic. The virus targets 
the immune system, T helper cells, specifically CD4 positive T cells, 
macrophages and dendritic cells. The socioeconomic impact is huge, and it 
represents a burden for the patient that needs to cope with the disease, the 
lifelong treatment and social stigma [1–3]. 
HIV has lately become a chronic condition with the introduction and 
development of antiviral therapy. In 2013 WHO (World Health Organization) 
recommended lifelong treatment regardless of CD4 count and viremia. This 
decision had a crucial impact on AIDS patient survivors [4– 8]. 
While the benefits of antiretroviral treatment are undebatable, there are 
concerns, especially about fetal side effects. There are few studies that tried to 
evaluate side effects in uninfected exposed children from HIV positive mothers, 
with conflicting results. It is extremely important to try to assess fetal antiviral 
side effects and to try to improve these children’s outcomes because the impact 
of HAART (highly active antiretroviral therapy) on vertical transmission and on 
the mother’s mortality and morbidity makes it vital. 
Previous literature data show that protease inhibitors have been 
associated with low progesterone production in trophoblastic cells and with the 
interference of CYP P450 (Cytochromes P45) enzymes. Low progesterone 
levels in pregnancy have been associated with fetal growth restriction (FGR), 
small for gestational age (SGA), premature birth, miscarriage, increased fetal 
morbidity and morbidity [9–13]. 
There is also scarce data about the influence of antiviral therapy on first 
trimester biochemical markers for aneuploidy. The influence of treatment on the 
values of PAPP-A (pregnancy-associated plasma protein A) and βHCG (Human 
chorionic gonadotropin) becomes very important in these patients because 
invasive fetal genetic testing raise the concern of increase vertical transmission. 
 
Objectives 
We tried to observe the modifications of first trimester biochemical 
markers for aneuploidy and serum progesterone levels in the first and the second 
trimester of pregnancy in HIV positive women under HAART therapy. 
 
MATERIAL AND METHODS 
This was a prospective study that took place between January 2017 and 
December 2019 in ʺCuza-Vodăʺ Hospital from Iasi, Romania. 
Inclusion criteria: HIV positive pregnant women under HAART therapy 
with complete obstetrical evaluations during pregnancy and with complete 
infectious disease evaluations during this time, with singleton pregnancy. 
Exclusion criteria: multiple pregnancies, incomplete obstetrical or 
infectious disease evaluations, patients under progesterone treatment for 
premature birth, patients with high risk for premature birth. 
All patients signed an informed consent approved by the ethical 
commission of Medicine and Pharmacy University ̋ Gr. T. Popaʺ, Iasi, Romania. 
We analysed first trimester PAPP-A, βHCG and progesterone of 25 HIV 
positive pregnant women under HAART therapy and second trimester 
progesterone of these patients. Ultrasound first trimester and second trimester 
evaluations were performed on Voluson E8 by two obstetricians trying to reduce 
the bias. 
The values obtained in the first trimester, between 11–13 weeks of 
gestation from HIV positive pregnant women were compared with the values 
from 31 seronegative pregnant women without any medical or obstetrical 
conditions. Later in the second trimester, between 24–28 weeks of gestation, 
progesterone levels of HIV positive pregnant women were compared to those 




Most of the 25 pregnant women were in C3 stage of disease (24% — 6 
cases) and came from rural areas. The age of these women was between 22–32 
years, except for only one case that was 37 years old. Most of them were in the 
long-term survivor category, meaning that they were HIV infected in early 
childhood during their hospitalisation for diverse pathology (92% — 23 cases). 
There were only two new cases in this group, both of them being infected 
through sexual contact by their partners. Only one case (4% of the cases) was at 
her third pregnancy, the rest, in equal percentage were at their first or second 
pregnancy (48%). All of them were under HAART therapy containing a 
protease inhibitor. Most of them were on Kaletra and Combivir associated 
treatment. Kaletra contains Lopinavir, a protease inhibitor and Ritonavir as a 
booster, both inhibiting CYP3A4 isoenzyme. Combivir is a combination 
between Lamivudine and Zidovudine, two nucleoside/nucleotide reverse- 
transcriptase inhibitors. 
Seventy-two percent of the 25 patients in our study had undetectable 
viral load (18 cases), five cases had low viral load under 201 copies/mL. Only 
two of them had detectable viremia: one was 10.700 copies/mL and one 6.060 
copies/mL (Fig. 2). 
All the data regarding serum dosing of aneuploidy markers and first and 
second trimester of pregnancy progesterone were analysed using One-way 
ANOVA test. 
The group of HIV positive patients had a slightly reduced mean age than 
the seronegative patients (27 years ± 3 years vs 28 years ± 4 years; p = 0.570), 
but a mean gestational age significantly higher (13 weeks and 1 day vs 12 weeks 
of gestation and 1 day; p = 0.002). 
Serum βHCG values and the values of the MoM for βHCG were 
significantly lower than the values of these parameters of normal pregnant 
women (24.25 vs 50.26 ng/mL; p = 0.007 and 0.77 vs 1.50; p = 0.002). 
PAPP-A serum levels and the MoM for PAPP-A were lower in HIV 
positive pregnant women than the values from seronegative pregnant women, 
but the difference was not statistically significant (3.74 vs 3.89; p = 0.876 and 
0.89 vs 1.22; p = 0.151). 
Progesterone levels were significantly lower between the two groups in 
both first and second trimester of pregnancy (21.79 vs 30.75; p = 0.001 and 
66.63 vs 136.36; p = 0.001). 
The rate of FGR/SGA in our study was 20%, three cases with FGR 
(under the third percentile for gestational age) and two cases with SGA (under 
the tenth percentile for gestational age). Twenty-four percent of the patients had 
premature birth, four at 36 weeks of gestation and only two between 34 and 36 
weeks. 
All patients gave birth by C-section and there were no children HIV 
infected after one year of life. 
 
DISCUSSION 
The huge positive impact of antiviral therapy in HIV positive patients is 
mildly shadowed by concerns about side effects, especially fetal side-effects. 
HIV positive pregnant women might be tempted to discontinue medication for 
the disease, due to worries about fetal health. There are few studies that tried to 
assess antiviral therapy side effects and to establish management directions to 
reduce their negative impact on exposed to antiviral HIV uninfected children. 
The prevalence of HIV exposed and antiviral exposed uninfected children 
raising due to the success of the therapy in prolonging lifespan and the reduction 
of the vertical transmission. So, it becomes very important to try to detect 
possible side effects and a real way to manage them in attempt to improve these 
children’s quality of life. 
Both serum first trimester markers for aneuploidy have lower values in 
HIV positive women under HAART therapy compared to HIV negative 
pregnant women with a more pronounced difference in βHCG levels. PAPP-A 
is a marker of successful development of the placenta in the first trimester of 
pregnancy. Lower levels of this marker reflect a disturbance in the early 
development of the placenta. 
Also, these alterations of the first trimester markers for aneuploidy in 
HIV positive pregnant women under HAART therapy might lead to an over 
estimation of the risk for Down syndrome. Fear of biased risk assessment might 
lead to unnecessary amniocentesis to exclude aneuploidy. Amniocentesis being 
an invasive procedure determines an increased risk for vertical transmission of 
the disease. In Poland, the cost of non-invasive fetal DNA testing form maternal 
blood is prohibitive and only a small number of patients can afford it [14, 15]. 
Prematurity represents a significant socio-economic burden. Fifteen 
million children are annually being born under 37 weeks of gestation. The 
management of morbidity and mortality of premature infants are more difficult 
in underdeveloped countries where the incidence of prematurity is also higher. 
HIV infection and antiretroviral therapy increases the risk of prematurity, 
especially protease inhibitors. Studies have shown that protease inhibitors cause 
FGR (fetal growth restriction), SGA (small for gestational age) fetuses and 
premature birth due to progesterone depletion. Our study is in concordance with 
the results in literature that HIV positive pregnant women under HAART 
therapy, which includes a protease inhibitor, have lower progesterone levels. 
Protease inhibitors interfere with the activity of cytochrome P450 enzymes and 
this seems to be the mechanism responsible for lower progesterone levels in 
these women. All the studies focused on dosing progesterone in the second or 
in the third trimester of pregnancy and relate it to prematurity. Our study tried 
to evaluate if the progesterone levels are being decreased since the first trimester 
of pregnancy, from the critical moment in which the placenta forms. Confirming 
progesterone depletion since the first trimester of pregnancy, associated with 
lower levels of PAPP-A, we have a possible explanation for placenta anomalies 
in HIV positive pregnant women that leads later to the development of fetal 
growth impairment like FGR and SGA. We chose not to dose serum 
progesterone after 32 weeks of gestation because there was an increase in 
progesterone levels due to placental transfer of this hormone fetal precursors [9–
12]. 
Both lower levels of progesterone and PAPP-A are associated with poor 
fetal outcome. Low levels of each of them are associated with increased risk for 
miscarriage, premature birth, SGA and FGR. Our results were similar to those 
of Chougrani et al who also observed a decrease in βHCG serum marker for 
aneuploidy in HIV positive pregnant women under HAART therapy with the 
underestimation of the risk for Down syndrome. [9, 12, 16]. 
None of our 25 patients had intermediary or high risk for aneuploidy. 
All the children were HIV negative after one year from birth. 
 
CONCLUSIONS 
Obstetricians need to know the alterations of the first trimester markers 
for aneuploidy that are present in this population so they can correctly advise 
these women accordingly. The ultrasound evaluation in these cases becomes 
more important because serum analysis can be a source of error and invasive 
testing stands under the risk of increased vertical transmission. 
To reduce the risk for unfavourable fetal outcome we can try 
supplementation with exogen progesterone. The decrease in this 
pregnancy essential hormone is related to premature birth, FGR and SGA 
fetuses. By administering progesterone, we can try to overcome and 
improve these outcomes. 
Because 18 of the HIV pregnant women from the 25 in our group 
had negative viremia, thus hypothetically the HIV virus effect is presumed 
to be absent, the alterations are due to antiretroviral treatment. And from 
the seven patients with detectable viremia, five had very low values, under 
201 copies/mL. 
Correct and complete information of these women about the risks and 
benefits of antiviral treatment, with management strategies to improve fetal 
outcomes might also assure a better compliance of the mothers to this 
treatment. 
From our knowledge it is the first study done in our country that 
evaluates these aspects. 
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Figure 2. Number of cases depending on the viral load 
 
 
Table 1. Evaluation of the serum first trimester aneuploidy markers and 
progesterone in the first and second trimester of pregnancy in HIV positive 
women under HAART therapy  
 




(n = 25) 
HIV negative 
(n = 31/24) 
Age (years ± SD) 27 years ± 3 
years 
28 years ± 4 
years 
0.570 
Gestational age (weeks ± SD) 13 weeks ± 1 
day 
12 weeks ± 1 
day 
0.002 
βHCG, ng/mL 25.45 ± 
13.18 
50.26 ± 42.20 0.007 
MoM βHCG 0.77 ± 0.44 1.50 ± 1.02 0.002 
PAPP-A m UI/mL 3.74 ± 2.16 3.89 ± 4.45 0.876 
MoM PAPP-A 0.89 ± 0.36 1.22 ± 1.09 0.151 
First trimester progesterone 
ng/mL 
21.79 ± 5.56 30.75 ± 9.10 0.001 







Viral load, U/mL ± SD 680 ± 200 negative  
 
